Our findings show that the new nomsotopic analog assays are effectively free of interferencefrom variationsin concentrationsof TBG and albumin, but may stillbe affected by the presence of autoantibodies to thyroxin. All gave lower mean values in pregnant patients.
To check the reliability of the Ames MPS paper spot test, which is based on the Azure A dye, we sent a seriesof urinesamples tothree laboratories where the spot testis part of the metabolic screening for mucopolysaccharidoses. In these laboratories false-negative results ranged between 19% and 35% and false-positive results ranged between 12% and 29% of all samples submitted. In contrast, the quantitative dimethylmethylene blue test (Clin Chem 1989;35:1472-7) detected an increased glycosaminoglycan content in allurinesamples from mucopolysaccharidosis patients and gave no false-positive results. In the latter procedure, glycosaminoglycan content is expressed per millimole of creatinine, and agedependent reference values are used. We conclude that the Ames spot test and other spot tests are unreliable as a screening procedure for mucopolysaccharidoses and should not be used to screen for these diseases. (4) .
In this investigation, we compared the reliability of the Ames MPS paper spot test with that of the DMB spectrophotometric test. We did this by sending a series of urine samples to various laboratories in the Netherlands where the spot test is part of the routine procedure for screening for these inborn errors of metabolism.
MaterIals and Methods
In a first approach to testthe reliability of the spot test,we sent 76 urine samples (48 normal specimens and 28 from patients with MPS) to laboratory 1. Because thisexperimental setup did not allow a directand objective comparison between the spottest and the DMB assay, we devised a second approach. An independent person, who did not take part in the screening for mucopolysaccharidoses in our laboratory, prepared three identical seriesof 75 urine specimens. Each series contained 26 samples from MPS patients, but thisnumber was not disclosed to the laboratories. All age categories were equally represented in the group of 49 urine specimens from normal subjects. Laboratories2 and 3 carried out the spot test. One serieswas analyzed in our laboratorywith the DMB assay. Only the sample number, the age of the person, and the creatimne content of the urine were known to the laboratories performing the spot test. The person performing the DMB test knew only the sample number. The calculation of the GAG content per millimole of creatimne and comparison with age-dependent reference values was carried out by a third (independent) person to prevent MPS urine samples from being recognized from the age of the patient or from the creatinine content of the urine.
Spot Test
The spottestwas performed with Ames MPS papers (Ames Co.,Div. ofMiles Labs. Inc., Elkhart, IN) according to the manufacturer's instructions. Spot testresults could be negative,dubious, trace,or positive. The latter three were allconsideredpositive results.
Dimethylmethylene Blue Assay
The DMB assay was performed with a Cobas-Fara >288 mg/L, which were found in some urine samples from patients with MPS, the urine was diluted10-fold before assay.
Urines
The urine samples analyzed were untimed urine portions. The patients were diagnosed by their clinical symptoms and low enzyme activity in leukocytes and cultured fibroblasts. The specific enzyme deficiencydetermined the particularsyndrome involved.
Results
In our initial study,involving 76 urine samples sent to laboratory1, the percentages of false-negative (2 1%) and false-positive results (29%) were unexpectedly high.
Six of the 28 MPS urine samples and 14 of the 48 normal urine samples were misidentified.
The investigationwas extended to two other labora-
tories (laboratories 2 and 3) to compare in a blind experimental design (see Materials and Methods) the spot testresults with the results of the DMB test (10) .
Results are given in Table 1 . The DMB test gave positiveresultsfor all MPS urine samples (sensitivity 100%), whereas for all the normal urine samples the GAG content by the DMB test was within the reference range (specificity 100%). With the spot test,however, 574 CLINICAL CHEMISTRY, Vol. 37, No. 4, 1991 laboratory 2 gave negative resultsforfiveofthe 26 MPS urine samples (sensitivity 81%) and 11 positive results for49 normal urine samples (specificity 78%). Laboratory 3 missed nine of 26 MPS urine samples (sensitivity 65%) and found positive results for six of 49 normal urine samples (specificity 88%). Figure 2 shows the GAG concentration as a function of age for the normal and MPS urine samples used in this study. MPS urine samples found negative in the spottestby one or more ofthe laboratories are indicated.
Discussion
For screeningprocedures,urine specimens are mostly random (untimed). The quantitativetestsdemonstrate that,depending on the type ofMPS, GAG excretioncan vary and will sometimes be only moderately increased Figure   1 ).
Measured GAG concentrationsvaried from 5 to 120 mgfL for normal urine samples, whereas 16 of 34 MPS urine samples had concentrations within this range. Thus, these MPS urine samples could notbe discriminated from normal urine samples by the spot test. Indeed, 12 of these 16 urine samples gave negative spot test results, and all falsely negative samples had GAG concentrations in this range (Figure 2A) . In contrast, all these urine samples had an increased GAG content when they were measured by the DMB assay and expressed as milligrams of GAG per millimole of creatinine ( Figure   2B ). We conclude from Figure 2A Rattenbury et al.(13) sent to 18 laboratories one MPS urine sample from a three-year-old patient with Sanfilippo's syndrome. Of the 14 responding laboratories, six gave an incorrect result, four of which involved a spot test (Toluidine Blue or Alcian Blue) as an initial screening procedure. Of the laboratories returning a correct result, none used a spot test.
Earlier (10), we described a new quantitative screening procedure, based on DMB dye, and established its reliability for screening for MPS. In the present study, the DMB procedure detected all the MPS patients and gave no false-positive results, whereas unacceptable percentages of false-negative and false-positive results were found with the spot test. In conclusion,
we consider the spot test to be unreliable and recommend that it no longer be used as an initial screeningprocedure.Instead,a simple,quantitative, and reliable procedure is available (10).
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